Clinical benefit of capsule endoscopy in Crohn's disease: Impact on patient management and prevalence of proximal small bowel involvement

Stephanie L. Hansel, Jeffrey D. McCurdy, John M. Barlow, Jeff Fidler, Joel Garland Fletcher, Brenda Becker, Nayantara Coelho Prabhu, William Alvis Faubion, Karen A. Hanson, Sunanda V. Kane, John B Kisiel, Edward Vincent Loftus, Jr, Konstantinos Papadakis, Darrell Spencer Pardi, Laura E. H. Raffals, Shayla Schoenoff, William J. Tremaine, David H Bruining

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Ileocolonoscopy and computed tomography (CT) or magnetic resonance (MR) enterography (CTE/MRE) are utilized to evaluate patients with small bowel (SB) Crohnfs disease (CD). The purpose of our study was to estimate the impact of capsule endoscopy (CE) on patient management after clinical assessment, ileocolonoscopy, and CTE/MRE. Methods: We prospectively analyzed 50 adult CD patients without strictures at clinically indicated ileocolonoscopy and CTE/MRE exams. Providers completed pre- and post-CE clinical management questionnaires. Pre-CE questionnaire assessed likelihood of active SBCD and management plan using a 5-point level of confidence (LOC) scales. Post-CE questionnaire assessed alteration in management plans and contribution of CE findings to these changes. A change of .2 on LOC scale was considered clinically meaningful. Results: Of the 50 patients evaluated (60% females), median age was 38 years, median disease duration was 3 years, and median Crohnfs Disease Activity Index (CDAI) score was 238 points. All CTE/MRE studies were negative for proximal disease. CE detected proximal disease in 14 patients (28%) with a median Lewis score of 215 points. CE findings altered management in 17 cases (34%). The most frequent provider-perceived benefits of CE were addition of new medication (29%) and exclusion of active SB mucosal disease (24%). Conclusion: CE is a safe imaging modality that alters clinical management in patients with established SBCD by adding incremental information not available at ileocolonoscopy and cross-sectional enterography.

Original languageEnglish (US)
Pages (from-to)1582-1588
Number of pages7
JournalInflammatory Bowel Diseases
Volume24
Issue number7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Capsule Endoscopy
Crohn Disease
Pathologic Constriction
Magnetic Resonance Spectroscopy
Tomography

Keywords

  • Capsule endoscopy/utilization
  • Crohn disease/diagnosis
  • Crohn disease/diagnostic imaging
  • Enterography

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Clinical benefit of capsule endoscopy in Crohn's disease : Impact on patient management and prevalence of proximal small bowel involvement. / Hansel, Stephanie L.; McCurdy, Jeffrey D.; Barlow, John M.; Fidler, Jeff; Fletcher, Joel Garland; Becker, Brenda; Prabhu, Nayantara Coelho; Faubion, William Alvis; Hanson, Karen A.; Kane, Sunanda V.; Kisiel, John B; Loftus, Jr, Edward Vincent; Papadakis, Konstantinos; Pardi, Darrell Spencer; Raffals, Laura E. H.; Schoenoff, Shayla; Tremaine, William J.; Bruining, David H.

In: Inflammatory Bowel Diseases, Vol. 24, No. 7, 01.01.2018, p. 1582-1588.

Research output: Contribution to journalArticle

Hansel, SL, McCurdy, JD, Barlow, JM, Fidler, J, Fletcher, JG, Becker, B, Prabhu, NC, Faubion, WA, Hanson, KA, Kane, SV, Kisiel, JB, Loftus, Jr, EV, Papadakis, K, Pardi, DS, Raffals, LEH, Schoenoff, S, Tremaine, WJ & Bruining, DH 2018, 'Clinical benefit of capsule endoscopy in Crohn's disease: Impact on patient management and prevalence of proximal small bowel involvement', Inflammatory Bowel Diseases, vol. 24, no. 7, pp. 1582-1588. https://doi.org/10.1093/ibd/izy050
Hansel, Stephanie L. ; McCurdy, Jeffrey D. ; Barlow, John M. ; Fidler, Jeff ; Fletcher, Joel Garland ; Becker, Brenda ; Prabhu, Nayantara Coelho ; Faubion, William Alvis ; Hanson, Karen A. ; Kane, Sunanda V. ; Kisiel, John B ; Loftus, Jr, Edward Vincent ; Papadakis, Konstantinos ; Pardi, Darrell Spencer ; Raffals, Laura E. H. ; Schoenoff, Shayla ; Tremaine, William J. ; Bruining, David H. / Clinical benefit of capsule endoscopy in Crohn's disease : Impact on patient management and prevalence of proximal small bowel involvement. In: Inflammatory Bowel Diseases. 2018 ; Vol. 24, No. 7. pp. 1582-1588.
@article{4fcb02f7671c407b8d102721e8518f8a,
title = "Clinical benefit of capsule endoscopy in Crohn's disease: Impact on patient management and prevalence of proximal small bowel involvement",
abstract = "Background: Ileocolonoscopy and computed tomography (CT) or magnetic resonance (MR) enterography (CTE/MRE) are utilized to evaluate patients with small bowel (SB) Crohnfs disease (CD). The purpose of our study was to estimate the impact of capsule endoscopy (CE) on patient management after clinical assessment, ileocolonoscopy, and CTE/MRE. Methods: We prospectively analyzed 50 adult CD patients without strictures at clinically indicated ileocolonoscopy and CTE/MRE exams. Providers completed pre- and post-CE clinical management questionnaires. Pre-CE questionnaire assessed likelihood of active SBCD and management plan using a 5-point level of confidence (LOC) scales. Post-CE questionnaire assessed alteration in management plans and contribution of CE findings to these changes. A change of .2 on LOC scale was considered clinically meaningful. Results: Of the 50 patients evaluated (60{\%} females), median age was 38 years, median disease duration was 3 years, and median Crohnfs Disease Activity Index (CDAI) score was 238 points. All CTE/MRE studies were negative for proximal disease. CE detected proximal disease in 14 patients (28{\%}) with a median Lewis score of 215 points. CE findings altered management in 17 cases (34{\%}). The most frequent provider-perceived benefits of CE were addition of new medication (29{\%}) and exclusion of active SB mucosal disease (24{\%}). Conclusion: CE is a safe imaging modality that alters clinical management in patients with established SBCD by adding incremental information not available at ileocolonoscopy and cross-sectional enterography.",
keywords = "Capsule endoscopy/utilization, Crohn disease/diagnosis, Crohn disease/diagnostic imaging, Enterography",
author = "Hansel, {Stephanie L.} and McCurdy, {Jeffrey D.} and Barlow, {John M.} and Jeff Fidler and Fletcher, {Joel Garland} and Brenda Becker and Prabhu, {Nayantara Coelho} and Faubion, {William Alvis} and Hanson, {Karen A.} and Kane, {Sunanda V.} and Kisiel, {John B} and {Loftus, Jr}, {Edward Vincent} and Konstantinos Papadakis and Pardi, {Darrell Spencer} and Raffals, {Laura E. H.} and Shayla Schoenoff and Tremaine, {William J.} and Bruining, {David H}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/ibd/izy050",
language = "English (US)",
volume = "24",
pages = "1582--1588",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Clinical benefit of capsule endoscopy in Crohn's disease

T2 - Impact on patient management and prevalence of proximal small bowel involvement

AU - Hansel, Stephanie L.

AU - McCurdy, Jeffrey D.

AU - Barlow, John M.

AU - Fidler, Jeff

AU - Fletcher, Joel Garland

AU - Becker, Brenda

AU - Prabhu, Nayantara Coelho

AU - Faubion, William Alvis

AU - Hanson, Karen A.

AU - Kane, Sunanda V.

AU - Kisiel, John B

AU - Loftus, Jr, Edward Vincent

AU - Papadakis, Konstantinos

AU - Pardi, Darrell Spencer

AU - Raffals, Laura E. H.

AU - Schoenoff, Shayla

AU - Tremaine, William J.

AU - Bruining, David H

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Ileocolonoscopy and computed tomography (CT) or magnetic resonance (MR) enterography (CTE/MRE) are utilized to evaluate patients with small bowel (SB) Crohnfs disease (CD). The purpose of our study was to estimate the impact of capsule endoscopy (CE) on patient management after clinical assessment, ileocolonoscopy, and CTE/MRE. Methods: We prospectively analyzed 50 adult CD patients without strictures at clinically indicated ileocolonoscopy and CTE/MRE exams. Providers completed pre- and post-CE clinical management questionnaires. Pre-CE questionnaire assessed likelihood of active SBCD and management plan using a 5-point level of confidence (LOC) scales. Post-CE questionnaire assessed alteration in management plans and contribution of CE findings to these changes. A change of .2 on LOC scale was considered clinically meaningful. Results: Of the 50 patients evaluated (60% females), median age was 38 years, median disease duration was 3 years, and median Crohnfs Disease Activity Index (CDAI) score was 238 points. All CTE/MRE studies were negative for proximal disease. CE detected proximal disease in 14 patients (28%) with a median Lewis score of 215 points. CE findings altered management in 17 cases (34%). The most frequent provider-perceived benefits of CE were addition of new medication (29%) and exclusion of active SB mucosal disease (24%). Conclusion: CE is a safe imaging modality that alters clinical management in patients with established SBCD by adding incremental information not available at ileocolonoscopy and cross-sectional enterography.

AB - Background: Ileocolonoscopy and computed tomography (CT) or magnetic resonance (MR) enterography (CTE/MRE) are utilized to evaluate patients with small bowel (SB) Crohnfs disease (CD). The purpose of our study was to estimate the impact of capsule endoscopy (CE) on patient management after clinical assessment, ileocolonoscopy, and CTE/MRE. Methods: We prospectively analyzed 50 adult CD patients without strictures at clinically indicated ileocolonoscopy and CTE/MRE exams. Providers completed pre- and post-CE clinical management questionnaires. Pre-CE questionnaire assessed likelihood of active SBCD and management plan using a 5-point level of confidence (LOC) scales. Post-CE questionnaire assessed alteration in management plans and contribution of CE findings to these changes. A change of .2 on LOC scale was considered clinically meaningful. Results: Of the 50 patients evaluated (60% females), median age was 38 years, median disease duration was 3 years, and median Crohnfs Disease Activity Index (CDAI) score was 238 points. All CTE/MRE studies were negative for proximal disease. CE detected proximal disease in 14 patients (28%) with a median Lewis score of 215 points. CE findings altered management in 17 cases (34%). The most frequent provider-perceived benefits of CE were addition of new medication (29%) and exclusion of active SB mucosal disease (24%). Conclusion: CE is a safe imaging modality that alters clinical management in patients with established SBCD by adding incremental information not available at ileocolonoscopy and cross-sectional enterography.

KW - Capsule endoscopy/utilization

KW - Crohn disease/diagnosis

KW - Crohn disease/diagnostic imaging

KW - Enterography

UR - http://www.scopus.com/inward/record.url?scp=85054205619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054205619&partnerID=8YFLogxK

U2 - 10.1093/ibd/izy050

DO - 10.1093/ibd/izy050

M3 - Article

C2 - 29788055

AN - SCOPUS:85054205619

VL - 24

SP - 1582

EP - 1588

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 7

ER -